UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Science translational medicine, 2015-03, Vol.7 (279), p.279ra40

2015

Volltextzugriff (PDF)

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia

PloS one, 2015-07, Vol.10 (7), p.e0131716-e0131716

2015

Volltextzugriff (PDF)

Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a

ACS medicinal chemistry letters, 2014-02, Vol.5 (2), p.205-209

2014

Volltextzugriff (PDF)

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation

Biochemical and biophysical research communications, 2017-09, Vol.491 (3), p.681-686

2017

Volltextzugriff (PDF)

Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis

ACS medicinal chemistry letters, 2019-11, Vol.10 (11), p.1543-1548

2019

Volltextzugriff (PDF)

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

Molecular cancer therapeutics, 2017-07, Vol.16 (7), p.1236-1245

2017

Volltextzugriff (PDF)

Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers

Current oncology (Toronto), 2022-12, Vol.29 (12), p.9928-9955

2022

Volltextzugriff (PDF)

Like a Queen

Atlanta review, 2017-03, Vol.23 (2), p.72

Tse, Chris

2017

Volltextzugriff (PDF)

INNV-23. UNDERSTANDING THE BURDEN OF MIDH1/2 DIFFUSE GLIOMA AND THE COMPLEXITY OF NAVIGATING THE PATIENT PATHWAY: INSIGHTS FROM PATIENTS AND CAREGIVERS

Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii173-viii173

2024

Volltextzugriff (PDF)

Like a queen

Atlanta review, 2016-04, Vol.23 (2), p.72-116

Tse, Chris

2016

Volltextzugriff (PDF)

Abstract 2127: Identification of a novel NAMPT inhibition resistance mechanism utilizing the de novo NAD+ biosynthesis pathway

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2127-2127

2016

Volltextzugriff (PDF)

Discovery of 4‑[(2R,4R)‑4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro‑2H‑chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis

Journal of medicinal chemistry, 2018-02, Vol.61 (4), p.1436-1449

2018

Volltextzugriff (PDF)

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

Molecular cancer therapeutics, 2011-12, Vol.10 (12), p.2340-2349

2011

Volltextzugriff (PDF)

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling

Molecular cancer therapeutics, 2024-01, Vol.23 (1), p.35-46

2024

Volltextzugriff (PDF)

A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab (pembro), lenvatinib, and chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC) harbouring a targetable mutation who experienced disease progression on standard tyrosine kinase inhibitors (TKIs)

Journal of clinical oncology, 2024-08, Vol.42 (23_suppl), p.198-198

2024

Volltextzugriff (PDF)

Structure-Guided Design of a Series of MCL‑1 Inhibitors with High Affinity and Selectivity

Journal of medicinal chemistry, 2015-03, Vol.58 (5), p.2180-2194

2015

Volltextzugriff (PDF)

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

The Journal of pharmacology and experimental therapeutics, 2020-01, Vol.372 (1), p.107-118

2020

Volltextzugriff (PDF)

Donated chemical probes for open science

eLife, 2018-04, Vol.7

2018

Volltextzugriff (PDF)

Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis

Bioorganic & medicinal chemistry letters, 2022-09, Vol.72, p.128843-128843, Article 128843

2022

Volltextzugriff (PDF)

Utilization of 18 F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo

The Journal of pharmacology and experimental therapeutics, 2019-12, Vol.371 (3), p.583-589

2019

Volltextzugriff (PDF)

Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells

BMC cancer, 2014-06, Vol.14 (1), p.430-430, Article 430

2014

Volltextzugriff (PDF)

COVD-11. THE BRAIN TUMOR AND NOT FOR PROFIT AND CHARITY EXPERIENCE OF COVID 19: REACTING AND ADJUSTING TO AN UNPRECEDENTED GLOBAL PANDEMIC IN THE 21ST CENTURY

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii23-ii23

2020

Volltextzugriff (PDF)

Discovery of 4-[(2 R ,4 R )-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2 H -chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis

Journal of medicinal chemistry, 2018-02, Vol.61 (4), p.1436-1449

2018

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(228)
Mit Volltextzugriff
(220)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(250)
Deutsch
(1)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia

Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation

Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers

Like a Queen

INNV-23. UNDERSTANDING THE BURDEN OF MIDH1/2 DIFFUSE GLIOMA AND THE COMPLEXITY OF NAVIGATING THE PATIENT PATHWAY: INSIGHTS FROM PATIENTS AND CAREGIVERS

Like a queen

Abstract 2127: Identification of a novel NAMPT inhibition resistance mechanism utilizing the de novo NAD+ biosynthesis pathway

Discovery of 4‑[(2R,4R)‑4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro‑2H‑chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling

Structure-Guided Design of a Series of MCL‑1 Inhibitors with High Affinity and Selectivity

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

Donated chemical probes for open science

Discovery of a Potent and Selective BCL‑XL Inhibitor with in Vivo Activity

Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis

Utilization of 18 F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo

Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells

COVD-11. THE BRAIN TUMOR AND NOT FOR PROFIT AND CHARITY EXPERIENCE OF COVID 19: REACTING AND ADJUSTING TO AN UNPRECEDENTED GLOBAL PANDEMIC IN THE 21ST CENTURY

Discovery of 4-[(2 R ,4 R )-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2 H -chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis

Suchergebnisse filtern